| |

2015

Dymista – CGC is responsible for communication on the gold standard in the treatment of allergic rhinitis. With the fixed combination of azelastine and budesonide in an innovative galenic, Meda SE introduced a highly effective nasal spray for allergic rhinoconjunctivitis (AR) to the German market in 2015. However, the market is characterized by a high…



weiterlesen

| |

2014

www.arztCME.de and the Medical Tribune cooperate The result is “arztCME plus“, one of the largest online continuing education platforms for doctors in the German-speaking world.



weiterlesen

| |

2014

European Network CGC is a partner of a newly established pan-European network of experienced, independent, specialist healthcare communications agencies. We offer an integrated global and local approach that combines our joint expertise of country-specific healthcare markets with a hard-to-find passion to deliver top-quality communications that make a genuine difference for our clients.



weiterlesen

| |

2011

Alexion: PR during the EHEC-crisis With the EHEC-crisis during the summer of 2011 the company that had thus far only been known to specialized medical doctors took center stage in the German media. 4,000 people, most of them in northern Germany, contract an EHEC infection, 400 of these patients develop the life-threatening hemolytic-uremic syndrome (HUS).…



weiterlesen

| |

2008

The molecular biologist Dr. Schrage has been sole managing partner at CGC since 2008.



weiterlesen

| |

since 2005

Actelion: Orphan disease PAH – unheard of yesterday, in the news today In 2005, PAH was an unknown indication, even within the groups of medical specialists confronted with the disease. In 2002, Actelion introduced a new class of substance – an oral dual endothelin receptor antagonist – that substantially improved the prognosis for patients affected…



weiterlesen

| |

since 2004

Repha: OTC-Benchmark-PR 2004 represented a break for many OTC drugs in Germany, because their reimbursement by health insurance companies was cut back almost entirely. In 2004, ANGOCIN Anti-Infekt N had already been on the market for almost 50 years. ANGOCIN has regulatory approval for two indications – that doesn’t necessarily make targeted communications easier. The…



weiterlesen

| |

2004

CME-certified exams: Launch of the online portal www.my-cme.de Since CGC is specialized in providing medical content, we offer high grade online-cme-exams for health professionals. Cooperating with our IT-partner company health & media since 2004, CGC has initiated the online education-portal www.my-cme.de.It is continuously refined by frequently offering new content from various indication areas and addressing…



weiterlesen

| |

2004

Reinforcing the CGC Management Team The medical and sociopolitical journalist Hans-Joachim Cramer was managing director at CGC till 2004, when Dr. Klaus Schrage joined the management team. Dr. Schrage had previously been marketing and sales director at a pharmaceutical company and was a very satisfied CGC customer.



weiterlesen

| |

2003

Cialis – the most successful launch in 2003 Communication of the USP of Cialis®, PR – support as from the pre-marketing stage: The best launch in 2003 succeeded in a market that was initially monopolistic and became highly competitive after the entry of Cialis®. Through trade media work the target group is increasingly conveyed that…



weiterlesen